TIPT

Ignore the headline ratios — they're artifacts, not fundamentals. Because the pending Fortegra sale reclassifies Fortegra (Tiptree's ~69.1%-owned insurer) into discontinued operations, the $488K 'revenue,' the 1,412x P/S and the -9,575% operating margin are just the leftover holding-company shell. What actually matters is the September 26, 2025 signed Sale Agreement: Tiptree and Warburg sell Fortegra for $1.65B cash, and MD&A pegs Tiptree's 69.1% share of the fair value of consideration at $1,121M with an estimated $419M gain on disposal. Against today's $689M market cap ($18.20 × 37.9M shares), that is a wide asset-value gap. Book value per share has compounded steadily ($11.34→$12.29→$13.45), and the ~$419M disposal gain would lift equity from $509M toward ~$928M, i.e. roughly $24/share of pro-forma book before tax and holdco discount — so the stock trades below the cash value coming in the door.

The reason this is a buy at only conviction 3, not a table-pounder, is governance and the stub. Management is explicit: Tiptree 'does not expect to distribute cash to its stockholders in connection with the Sale,' will have 'broad discretion in the use of the proceeds,' and 'may use proceeds in ways that stockholders may not approve' — any return is expected to come only through the share price. So realization depends entirely on redeployment by a Tiptree/Warburg-controlled holdco, not a check to shareholders. Meanwhile the Retained Business is a cash-burner: FY2025 continuing operations lost $38.9M, driven by $33.8M of employee comp (incl. $6.7M stock comp) and public-company costs, and MD&A warns those fixed costs become 'a much larger percentage of revenues' post-sale. The dividend was already cut ~50% to $9.07M.